Sanofi - 02 Aug 2021 Form 4 Insider Report for Icosavax, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 02 Aug 2021
Net transaction value: +$1,000,005
SEC form: 4
Accepted by SEC: 02 Aug 2021, 20:34:24 UTC
Prior SEC filing: 28 Jul 2021
Next SEC filing: 14 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Alexander Roger, Head of Securities Law and Capital Markets

Key filing fact

Sanofi filed Form 4 for Icosavax, Inc. on 02 Aug 2021.

Key facts

This page summarizes Sanofi's Form 4 filing for Icosavax, Inc..
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Aug 2021, 20:34.

Change

Previous filing in this sequence was filed on 28 Jul 2021.
Current net transaction value: +$1,000,005.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ICVX transaction

Common Stock (par value, $0.0001)

Conversion of derivative security

Transaction value: $0
Shares: +3,088,502
Change %
Price: $0.000000
Shares after: 3,088,502
Date: 02 Aug 2021
Ownership: Through its wholly-owned subsidiary, Aventis Inc.
Footnotes: F1, F2

ICVX transaction

Common Stock (par value, $0.0001)

Purchase

Transaction value: $1,000,005
Shares: +66,667
Change %: +2.2%
Price: $15.00
Shares after: 3,155,169
Date: 02 Aug 2021
Ownership: Through its wholly-owned subsidiary, Aventis Inc.
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ICVX transaction Derivative

Series A-1 Preferred Stock (par value, $0.0001)

Conversion of derivative security

Transaction value
Shares: -12,480,498
Change %: -100%
Price
Shares after: 0
Date: 02 Aug 2021
Ownership: Through its wholly-owned subsidiary, Aventis Inc
Underlying class: Common Stock
Underlying amount: 3,003,224
Exercise price: $0.000000
Footnotes: F1, F2

ICVX transaction Derivative

Series B-1 Preferred Stock (par value, $0.0001)

Conversion of derivative security

Transaction value
Shares: -354,393
Change %: -100%
Price
Shares after: 0
Date: 02 Aug 2021
Ownership: Through its wholly-owned subsidiary, Aventis Inc
Underlying class: Common Stock
Underlying amount: 85,278
Exercise price: $0.000000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Sanofi is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer.

Footnote F2

Sanofi is the beneficial owner of 3,155,169 Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc.

Footnote F3

The reporting person acquired additional shares in the Issuer's initial public offering.